➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,828,440

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,828,440 protect, and when does it expire?

Patent 8,828,440 protects ZILRETTA and is included in one NDA.

This patent has fifty patent family members in twenty-one countries.

Summary for Patent: 8,828,440
Title:Corticosteroids for the treatment of joint pain
Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
Inventor(s): Bodick; Neil (Boston, MA), Blanks; Robert C. (Auburndale, MA), Kumar; Anjali (Belmont, MA), Clayman; Michael D. (Gloucester, MA), Moran; Mark (Orinda, CA)
Assignee: Flexion Therapeutics, Inc. (Burlington, MA)
Application Number:13/422,994
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 8,828,440

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Flexion Theraps Inc ZILRETTA triamcinolone acetonide FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR 208845-001 Oct 6, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,828,440

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 082471 ⤷  Free Forever Trial
Australia 2011285691 ⤷  Free Forever Trial
Australia 2012290683 ⤷  Free Forever Trial
Australia 2015268647 ⤷  Free Forever Trial
Australia 2017245408 ⤷  Free Forever Trial
Australia 2017268620 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.